DNAtrix and Valo Therapeutics Enter into Strategic Partnership to Develop Peptide-Coated Oncolytic Viruses for Treating Cancer (PR Newswire)

UF startup DNAtrix and Valo Therapeutics announced an exclusive R&D collaboration to develop enhanced vaccines using DNAtrix’s clinical stage viruses and Valo’s proprietary antigenic peptide technology.

DNAtrix’s clinical stage oncolytic adenovirus platform and Valo’s PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus) vaccination technology will be combined to generate a novel “armed oncolytic vaccine” for cancer therapy. While oncolytic adenoviruses alone offer a promising strategy to treat cancer, in combination with PeptiCRAd, superior and durable immunological protection against most forms of solid tumors is expected. Given the ease with which this therapy can be adapted for emerging neoantigens, it has significant potential as a personalized therapeutic capable of focusing the immune system on generating cancer specific CD8+ (killer) T cells on a case by case basis.

Learn more about DNAtrix and Valo Therapeutics Enter into Strategic Partnership to Develop Peptide-Coated Oncolytic Viruses for Treating Cancer.